Overview
Ashland fiscal Q4 revenue down 8% yr/yr, missing analyst expectations
Adjusted EBITDA for fiscal Q4 beats analyst estimates, reflecting operational efficiency
Company received $103 mln tax refund, strengthening financial position
Outlook
Ashland expects fiscal 2026 sales between $1,835 mln and $1,905 mln
Company forecasts adjusted EBITDA of $400 mln to $430 mln for fiscal 2026
Ashland anticipates double-digit-plus growth in adjusted EPS excluding intangibles amortization
Result Drivers
PORTFOLIO OPTIMIZATION - Reduced sales by $38 mln due to divestitures and product line exits, impacting overall revenue
LIFE SCIENCES DEMAND - Stable demand in pharmaceuticals driven by innovation and high-value excipients
PERSONAL CARE GROWTH - Strong growth due to strategic investments and innovation across end markets
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$478 mln
$480.55 mln (7 Analysts)
Q4 EPS
$0.71
Q4 Net Income
$32 mln
Q4 Adjusted EBITDA
Beat
$119 mln
$118.26 mln (10 Analysts)
Q4 Free Cash Flow
$52 mln
Press Release: ID:nGNX49W8yt
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)